Apellis Pharmaceuticals Announces That APL-2 Met Its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-...
August 24, 2017
MaxCyte, Inc. - First Day of Dealings on AIM
March 30, 2016
Apellis Pharmaceuticals Announces Pricing of Initial Public Offering
November 8, 2017
Potentia Pharmaceuticals Hosts Reception at the 2006 ARVO Annual Meeting in Fort Lauderdale
April 3, 2006
Potentia hosted a reception in Fort Lauderdale during the Association for Research in Vision and Ophthalmology (ARVO) annual meeting. The event brought together the entire Potentia team and Scientific Advisory Board, along with collaborators and potential partners and introduced them to Potentia and its focused developmental timetable. The reception was a frank success and approximately 35 people attended.